Eli Lilly and (LLY)
| Bid | 746 |
| Market Cap | 707.8B |
| Revenue (ttm) | 45.04B |
| Net Income (ttm) | 10.59B |
| EPS (ttm) | 11.72 |
| PE Ratio (ttm) | 63.71 |
| Forward PE | 35.77 |
| Analyst | Buy |
| Ask | 747.09 |
| Volume | 1,515,936 |
| Avg. Volume (20D) | 3,969,300.8 |
| Open | 750.45 |
| Previous Close | 732.41 |
| Day's Range | 734.52 - 755.41 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.50 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer ...
Analyst Forecast
According to 24 analyst ratings, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $1008, which is an increase of 35.01% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
19 hours ago · seekingalpha.com
Eli Lilly: Still Great, But Still Too Expensive Even As Earnings NearEli Lilly has shown strong financial performance, driven by key drugs like Mounjaro and Zepbound, but shares remain expensive relative to peers, justifying a 'hold' rating. Revenue, profits, and cash ...
